Pituitary

, Volume 16, Issue 4, pp 545–553 | Cite as

Prevalence and incidence of pituitary adenomas: a population based study in Malta

  • Mark Gruppetta
  • Cecilia Mercieca
  • Josanne Vassallo
Article
First Online:

Abstract

Epidemiological data is important to correctly quantify the extent of disease and needed health care resources. The aim of the study was to establish the prevalence and incidence of pituitary adenomas (PAs) in the same well defined population, with in-depth analysis of the various subtypes. The design involved a retrospective cross-sectional analysis of PA patients diagnosed prior to 31 July 2011 for prevalence estimates and those diagnosed between July 2000 and July 2011 for incidence estimation. A thorough search for patients with PAs was carried out in central hospital registries including outpatients departments, surgical registries, radiological department and specialty clinic databases. Prevalence rates/100,000 and Standardised incidence ratios (SIR)/100,000/year were worked out. The respective prevalence rates and SIR for PAs overall were 75.7/100,000, and 4.27/100,000/year, for Prolactinomas 35.0/100,000 and 2.05/100,000/year, for nonfunctioning PA 25.9/100,000 and 1.79/100,000/year and for GH-secreting PAs 12.5/100,000 and 0.31/100,000/year. The overall prevalence for macroadenomas was 32.8/100,000 and SIR was 1.49/100,000/year. The prevalence rate in males for PAs overall was 46.3/100,000 and SIR was 2.08/100,000/year and in females 104.8/100,000 and SIR was 6.58/100,000/year. Females had a lower proportion of macroadenomas than males (29.5 vs. 75.0 %; P < 0.001) and macroadenomas tended to present at a later age compared to microadenomas (48 vs. 34.5; P < 0.001). The highest SIR was reached in the 30–39 age group at 7.42/100,000/year. Our data confirm the considerable disease burden that PAs bear on health care resources. Males and females have similar prevalence and SIR rates for macroadenomas but there is a significant increase in SIR in females of child bearing age compared to males. These observations may have important implications in terms of the economic burden and need for early intervention.

Keywords

Prevalence Incidence Pituitary adenoma 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

The authors would like to acknowledge all the medical specialists and other healthcare staff at Mater Dei Hospital who gave invaluable support during the course of this study.

Conflict of interest

None.

References

  1. 1.
    Dekkers OM, van der Klaauw AA, Pereira AM, Biermasz NR, Honkoop PJ, Roelfsema F, Smit JW, Romijn JA (2006) Quality of life is decreased after treatment for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 91:3364–3369PubMedCrossRefGoogle Scholar
  2. 2.
    Matta MP, Couture E, Cazals L, Vezzosi D, Bennet A, Caron P (2008) Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance. Eur J Endocrinol 158:305–310PubMedCrossRefGoogle Scholar
  3. 3.
    Van der Klaauw AA, Kars M, Biermasz NR, Roelfsema F, Dekkers OM, Corssmit EP, van Aken MO, Havekes B, Pereira AM, Pijl H, Smit JW, Romijn JA (2008) Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas. Clin Endocrinol (Oxf) 69:775–784CrossRefGoogle Scholar
  4. 4.
    Sughrue ME, Chang EF, Gabriel RA, Aghi MK, Blevins LS (2011) Excess mortality for patients with residual disease following resection of pituitary adenomas. Pituitary 14:276–283PubMedCrossRefGoogle Scholar
  5. 5.
    Siqueira MG, Guembarovski AL (1984) Subclinical pituitary microadenomas. Surg Neurol 22:134–140PubMedCrossRefGoogle Scholar
  6. 6.
    Teramoto A, Hirakawa K, Sanno N, Osamura Y (1994) Incidental pituitary lesions in 1,000 unselected autopsy specimens. Radiology 193:161–164PubMedGoogle Scholar
  7. 7.
    Tomita T, Gates E (1999) Pituitary adenomas and granular cell tumors: incidence, cell type, and location of tumor in 100 pituitary glands at autopsy. Am J Clin Pathol 111:817–825PubMedGoogle Scholar
  8. 8.
    Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH (1994) Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 120:817–820PubMedCrossRefGoogle Scholar
  9. 9.
    Chong BW, Kucharczyk W, Singer W, George S (1994) Pituitary gland MR: a comparative study of healthy volunteers and patients with microadenomas. Am J Neuroradiol 15:675–679PubMedGoogle Scholar
  10. 10.
    Mindermann T, Wilson CB (1994) Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol (Oxf) 41:359–364CrossRefGoogle Scholar
  11. 11.
    Nilsson B, Gustavasson-Kadaka E, Bengtsson BA, Jonsson B (2000) Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality. J Clin Endocrinol Metab 85:1420–1425PubMedCrossRefGoogle Scholar
  12. 12.
    Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91:4769–4775PubMedCrossRefGoogle Scholar
  13. 13.
    Fernandez A, Karavitaki N, Wass JA (2009) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72:377–382CrossRefGoogle Scholar
  14. 14.
    Fontana E, Gaillard R (2009) Epidemiology of pituitary adenoma: results of the first Swiss study. Rev Med Suisse 5:2172–2174PubMedGoogle Scholar
  15. 15.
    Raappana A, Koivukangas J, Ebeling T, Pirilä T (2010) Incidence of pituitary adenomas in Northern Finland in 1992–2007. J Clin Endocrinol Metab 95:4268–4275PubMedCrossRefGoogle Scholar
  16. 16.
    Daly AF, Tichomirowa MA, Beckers A (2009) The epidemiology and genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 23:543–554PubMedCrossRefGoogle Scholar
  17. 17.
    Ahmad OE, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R, Inoue M (2000) Age standardization of rates: a new WHO standard. GPE discussion paper series 31. World Health Organization, GenevaGoogle Scholar
  18. 18.
    Davis JRE, Farrell WE, Clayton RN (2000) Pituitary tumours. Reproduction 121:363–371CrossRefGoogle Scholar
  19. 19.
    Ciccarelli A, Daly AF, Beckers A (2005) The epidemiology of prolactinomas. Pituitary 8:3–6PubMedCrossRefGoogle Scholar
  20. 20.
    Colao A (2009) The prolactinoma. Best Pract Res Clin Endocrinol Metab 23:575–596PubMedCrossRefGoogle Scholar
  21. 21.
    Molitch ME (2009) Pituitary tumours: pituitary incidentalomas. Best Pract Res Clin Endocrinol Metab 23:667–675PubMedCrossRefGoogle Scholar
  22. 22.
    Franks S, Nabarro JDN, Jacobs HS (1977) Prevalence and presentations of hyperprolactinaemia in patients with “functionless” pituitary tumours. Lancet 309:778–780CrossRefGoogle Scholar
  23. 23.
    Murad MH, Fernández-Balsells MM, Barwise A, Gallegos-Orozco JF, Paul A, Lane MA, Lampropulos JF, Natividad I, Perestelo-Pérez L, Ponce de León-Lovatón PG, Albuquerque FN, Carey J, Erwin PJ, Montori VM (2010) Outcomes of surgical treatment for nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 73:777–791CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Mark Gruppetta
    • 1
    • 2
  • Cecilia Mercieca
    • 1
  • Josanne Vassallo
    • 1
    • 2
  1. 1.Department of Medicine, Faculty of Medicine and Surgery, Mater Dei HospitalUniversity of MaltaMsidaMalta
  2. 2.Neuroendocrine ClinicMater Dei HospitalMsidaMalta

Personalised recommendations